<DOC>
	<DOCNO>NCT00018538</DOCNO>
	<brief_summary>Prostate cancer common occurrence age population , one ten men destine develop disease . 40 % patient prostate cancer experience recurrence definitive treatment . This study address as-yet unresolved problem optimal management early recurrence manifest increase accept marker disease , PSA . Vitamin D , agent cell-differentiating property , show inhibit angiogenesis cause differentiation prostate cancer cell laboratory affect PSA favorably clinical study patient advanced prostate cancer . This study assess effect vitamin D patient sub-clinical biochemical relapse prostate cancer indicate rise PSA low tumor burden , potential develop approach problem delay prevent progression .</brief_summary>
	<brief_title>Calcifidol Therapy Men With Cancer</brief_title>
	<detailed_description />
	<criteria>Patients male three successive rise PSA achieve nadir postdefinitive therapy . The following criterion must meet : pathologically confirm prostate cancer , completion definitive treatment form local external beam radiation definitive surgery three successive rise PSA clinical evidence disease .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2004</verification_date>
	<keyword>vitamin D</keyword>
	<keyword>prostatic neoplasm</keyword>
	<keyword>neoplasm recurrence</keyword>
</DOC>